

6 November 2015

Dear Dr Sample,

RE: G0000-00000-Sample-FS

Please find enclosed our Journal Recommendations Report for your manuscript, "Effect of hematocrit on tacrolimus concentration".

We have prepared our Journal Recommendations Report based on your suggestion of journals that have an impact factor between 0.9 and 4. We note that the manuscript has previously been rejected by the *American Journal of Transplantation* after peer review and that you have identified *Therapeutic Drug Monitoring* as a potential target for resubmission.

We agree that *Therapeutic Drug Monitoring* is a good choice of target journal for your manuscript. When resubmitting a rejected manuscript to a new journal, it is important not to choose a journal with very similar aims and outlook to avoid a similar outcome. In our opinion, *Therapeutic Drug Monitoring* would be a good target because it has a more global outlook than the *American Journal of Transplantation*, and the lower impact factor makes acceptance of your manuscript more likely.

You might also wish to consider submitting your manuscript to *Xenobiotica*. It has a similar impact factor, but publishes molecular and animal pharmacology and toxicology studies as well as human and clinical studies. This gives it a broader audience, which you may find appealing. We judge that the likelihood of acceptance is approximately the same as for *Therapeutic Drug Monitoring*.

If neither of these journals accepts your manuscript, there are two fallback options. The first is *Transplantation Proceedings*, a slightly less prestigious journal reflected by its lower impact factor. However, because it is a transplantation journal, it has a different audience to the two journals suggested above, and the reviewers are likely to be clinicians. This could substantially increase the chances of acceptance for your manuscript, with your study having a strong clinical focus.

The second fallback option is *BMC Pharmacology and Toxicology*, a relatively new open access online journal that does not yet have an impact factor, but that is indexed on PubMed and Medline. It will likely receive an impact factor this year or next. *BMC Pharmacology and Toxicology* is an exclusively online journal, it is widely read, and the editors should make a fast decision on your manuscript. However, as it is an open access journal, it charges a publication fee (US\$2,145).

Overall, we believe that *Therapeutic Drug Monitoring* offers the most appropriate initial target. It is likely that they will provide initial feedback on whether your manuscript will be considered or not relatively quickly, to give you the opportunity to then change to an alternative publication. If *Therapeutic Drug Monitoring* is not willing to publish your manuscript, we recommend approaching the following alternative journals in the order presented:

2. *Xenobiotica*
3. *Transplantation Proceedings*
4. *BMC Pharmacology and Toxicology*.

The next step is for you to confirm your choice of journal for submission. Once we receive this information, we will proceed to edit the manuscript to ensure that its language meets an acceptable level and that its style and formatting are appropriate for the journal you have selected. However,

please note that depending on which journal you choose and the article type of your manuscript, you may need to reformat your current manuscript (e.g., word limits or references) so that it complies with journal requirements. We recommend that you review the journal guidelines for our recommended journals before making a final decision.

Although we try to identify the most appropriate journals for your manuscript, please note that our suggestions cannot guarantee consideration or acceptance by these journals.

We hope these suggestions help you to choose the most appropriate target journal for your manuscript.

Yours sincerely,

Edanz Group Global
global@edanzgroup.com